Trial Profile
An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients with at least 65 years of age with essential hypertension, using 24-hour ABPM [ambulatory BP monitoring], with lisinopril 10 mg as a reference.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Lisinopril
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 05 Nov 2005 New trial record.